Drugs / Insulin Degludec/liraglutide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06559722 | Aug 2024 → Oct 2025 overdue | type 2 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Degludec/liraglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06559722 ↗ |
| Route | Subcutaneous | “Subcutaneously (s.c., under the skin) administration once daily” NCT06559722 ↗ |